Fang Jin is a highly motivated and inquisitive Principal Scientist at Pfizer, where he plays a pivotal role in advancing therapeutic antibody development. With a proven track record of leadership, Fang has successfully guided numerous projects through various stages, from molecule design to patent invention...
Fang Jin is a highly motivated and inquisitive Principal Scientist at Pfizer, where he plays a pivotal role in advancing therapeutic antibody development. With a proven track record of leadership, Fang has successfully guided numerous projects through various stages, from molecule design to patent invention and ultimately to Investigational New Drug (IND) applications. His expertise lies in antibody engineering, particularly in the development of innovative modalities such as trispecific antibodies, monoclonal antibodies (mAbs), and antibody-drug conjugates (ADCs).
Currently, Fang leads cross-functional teams within the oncology and inflammation therapeutic areas, collaborating closely with therapeutic area leaders and downstream partner lines to ensure seamless project execution. His hands-on experience in target validation and extensive knowledge of biochemistry and molecular biology enable him to navigate complex challenges in drug discovery effectively. Notably, he spearheaded a trispecific project that not only achieved significant milestones but also resulted in a patent that underscores the innovative nature of his work.
Fang's technical skills are complemented by his proficiency in in vitro transcription (IVT), FACS analysis, cell culture, and purification techniques, which are essential for the rigorous demands of biopharmaceutical development. His ability to integrate scientific insights with strategic project management makes him a valuable asset to Pfizer and a key contributor to the advancement of cutting-edge therapies in the life sciences sector. As Fang continues to push the boundaries of antibody engineering, he remains committed to delivering impactful solutions that address unmet medical needs.